Therapeutic Goods (European Community and non–EC/EFTA MRA) Declaration 2022

Overview

The Therapeutic Goods (European Community and non-EC/EFTA MRA) Declaration 2022 was enacted to update the list of countries recognised under the Therapeutic Goods Act 1989, ensuring compliance with mutual recognition agreements (MRA) for the regulation of therapeutic goods. This notifiable instrument was made by Jennifer Burnett, as delegate of the Minister for Health and Aged Care, under sections 3A and 3B of the Therapeutic Goods Act 1989. The policy objective of the declaration is to facilitate the recognition of regulatory decisions and processes in the member states of the European Community, European Free Trade Association, and countries covered by non-EC/EFTA MRAs, thereby enhancing the efficiency and effectiveness of the regulation of therapeutic goods in Australia. This declaration replaces previous declarations and repeals outdated instruments to streamline the regulatory framework.

Scope and Application

The Therapeutic Goods (European Community and non-EC/EFTA MRA) Declaration 2022 is made under the authority of the Therapeutic Goods Act 1989 and applies to the declaration of certain European and non-European countries under mutual recognition agreements. The Act pertains to entities and individuals engaged in the importation, manufacture, or supply of therapeutic goods within Australia that seek to leverage these agreements for regulatory compliance. Geographically, the Act extends to the Commonwealth of Australia, providing a regulatory framework that recognises certain European and non-European countries for the purposes of mutual recognition arrangements in the therapeutic goods sector. The application of this Act is limited to those countries specifically listed in the schedules, and it does not apply to any other jurisdictions outside of those declarations. The Act also repeals previous declarations made under the Therapeutic Goods Act to ensure that only the most current recognitions are in force. This declaration is effective from the day after its registration and serves to streamline regulatory processes for therapeutic goods across specified jurisdictions.

Key Provisions

The Therapeutic Goods (European Community and non-EC/EFTA MRA) Declaration 2022 (section 1) declares certain countries as members of the European Community or European Free Trade Association (EFTA) and specifies countries covered by non-EC/EFTA Mutual Recognition Agreements (MRA). The commencement of the instrument occurs the day after it is registered (section 2). The authority for making this instrument is under sections 3A and 3B of the Therapeutic Goods Act 1989 (section 3). Key terms such as "member of the European Community" and "non-EC/EFTA MRA" are defined both in the Act and within this instrument (section 4). Specifically, section 5 declares certain countries as members of the European Community or EFTA, while section 6 declares countries covered by non-EC/EFTA MRAs. Finally, section 7 repeals previous instruments related to these declarations. The Act imposes obligations on the parties it governs, specifically those involved in the importation, exportation, or distribution of therapeutic goods within Australia. These entities must ensure compliance with the Therapeutic Goods Act 1989 and the regulations made under it. They must also adhere to the declarations made under this instrument regarding the recognition of certain countries' regulatory standards for therapeutic goods. This means that goods approved in these countries can be more easily marketed and sold in Australia, provided they meet the standards set forth in the MRAs. Entities must also ensure that any therapeutic goods entering Australia from these countries comply with Australian regulations and standards. The Therapeutic Goods (European Community and non-EC/EFTA MRA) Declaration 2022 does not explicitly outline specific offences, penalties, or consequences for breaches within the text. However, the Therapeutic Goods Act 1989 does provide for a range of penalties for breaches of the Act and regulations made under it. These penalties can include fines, imprisonment, or both, depending on the severity of the offence. For instance, section 22 of the Act provides for penalties for offences involving the supply of therapeutic goods that do not comply with the Act, with maximum penalties reaching up to $5.5 million for corporations and $110,000 for individuals, along with potential imprisonment terms. Additionally, section 37 of the Act allows for the imposition of civil penalties for breaches of the Act, with fines that can reach up to $275,000 for corporations and $55,000 for individuals. These penalties underscore the importance of compliance with the Act and the associated declarations.